Vaxart (VXRT) CEO Finney reports RSU vesting, 54,153 shares withheld for taxes

Rhea-AI Filing Summary

Vaxart, Inc. insider Michael Finney reported equity transactions in company stock. On December 4, 2025, he acquired 151,351 shares of common stock at a price of $0, reflecting the full vesting of previously granted restricted stock units. On the same date, 54,153 shares were disposed of at $0.37 per share, representing shares withheld by Vaxart to cover income tax obligations tied to the RSU vesting.

After these transactions, Finney beneficially owns 1,787,559 shares of Vaxart common stock directly, plus 100,000 shares held indirectly through the Lo Family Trust. The reported holdings also include 57,723 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Lo Steven

Role President, Chief Exec Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	151,351	$0.00	--
Tax Withholding	Common Stock	54,153	$0.37	$20K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,841,712 shares (Direct); Common Stock — 100,000 shares (Indirect, By the Lo Family Trust)

Footnotes (1)

1. Grant of shares upon vesting of restricted stock units, which fully vested on December 4, 2025. This amount includes 57,723 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of December 4, 2025.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lo Steven

(Last) (First) (Middle)

C/O VAXART, INC.

170 HARBOR WAY, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vaxart, Inc. [ VXRT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, Chief Exec Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/04/2025		A		151,351(1)	A	$0	1,841,712(2)	D
Common Stock	12/04/2025		F		54,153(3)	D	$0.37	1,787,559	D
Common Stock								100,000	I	By the Lo Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of shares upon vesting of restricted stock units, which fully vested on December 4, 2025.

2. This amount includes 57,723 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan.

3. Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of December 4, 2025.

	/s/ Edward Berg, Attorney-in-Fact	12/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Vaxart (VXRT) report for December 4, 2025?

Vaxart (VXRT) reported that President and Chief Executive Officer Michael Finney received 151,351 shares of common stock on December 4, 2025 upon the full vesting of restricted stock units, with a stated price of $0 per share.

Why were 54,153 Vaxart (VXRT) shares disposed of at $0.37 by the CEO?

The 54,153 shares of Vaxart common stock disposed of at $0.37 per share represent shares withheld by the company to satisfy its income tax withholding and remittance obligations in connection with the RSUs that vested on December 4, 2025.

How many Vaxart (VXRT) shares does the CEO beneficially own after these transactions?

Following the reported transactions, Michael Finney beneficially owns 1,787,559 shares of Vaxart common stock directly and 100,000 shares indirectly, which are held by the Lo Family Trust.

What is the role of the reporting person in Vaxart (VXRT)?

The reporting person is a Director and an Officer of Vaxart, serving as President and Chief Executive Officer.

What does the 151,351-share grant to the Vaxart (VXRT) CEO represent?

The 151,351-share grant represents shares issued upon the vesting of restricted stock units, which fully vested on December 4, 2025.

What additional Vaxart (VXRT) shares are included from the employee stock purchase plan?

The reported beneficial ownership amount includes 57,723 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan.

Is this Vaxart (VXRT) Form 4 filed for one or multiple reporting persons?

This Form 4 is indicated as being filed by one reporting person, not by a group.